AuntMinnie
MARCH 15, 2024
A 2018 study from the U.S. An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Americans today can expect to live long lives.
AuntMinnie
JULY 26, 2024
Evidence showed that Sheriff owned and was pharmacist in charge at Shertech, a pharmacy that provided nuclear and radiopharmaceutical drugs to medical facilities. Attorney's Office in the District of South Carolina.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
MAY 1, 2024
Food and Drug Administration (FDA) has approved Novartis' Lutathera (lutetium-177 [Lu-177]) DOTATATE radiopharmaceutical for treatment of pediatric patients who are 12 years old and older with somatostatin receptor (SSTR)-positive gastroentropancreatic neuroendocrine tumors (GEP-NETs).
Imaging Technology
APRIL 10, 2024
an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,
Imaging Technology
JUNE 15, 2023
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,
AuntMinnie
JANUARY 30, 2024
In 2018, Alosco received nearly $800,000 from the National Institutes of Health's National Institute of Neurological Disorders and Stroke for the research. A widely used class of radiopharmaceuticals in the study of the neuroinflammatory response targets the translocator protein (TSPO), according to the researchers.
AuntMinnie
OCTOBER 25, 2024
In 2018 he received an endowed professorship from the university. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year.
Expert insights. Personalized for you.
264 
Let's personalize your content